← All organizations
Highest phase reached
Phase 4
First clinical trial
Jan 1, 2011Last known activity
Jan 5, 2026
Timeline
2010s
- Jan 1, 2011
National Center for Advancing Translational Science (NCATS)— Founded
Drugs by trial phase (75 distinct, 66 trials)
Phase 4 (13 own, 0 via acquisition)
Phase 3 (21 own, 0 via acquisition)
Phase 2 (26 own, 0 via acquisition)
Phase 1 (10 own, 0 via acquisition)
Other trials (5 own, 0 via acquisition)
Indications
Studied for
- Alcohol Drinking
- Alcoholism
- Alcohol-Related Disorders
- Aortic Valve Stenosis
- Atrophic Vaginitis
- Atrophy
- Autoimmune Diseases
- Borderline Personality Disorder
- Chronic Pain
- Constriction, Pathologic
- Digestive System Diseases
- Distal Myopathies
- Eosinophilic Esophagitis
- Esophagitis
- Fibrosis
- Gangliosidoses
- Gangliosidoses, GM2
- Gangliosidosis, GM1
- Gastrointestinal Diseases
- Gaucher Disease
- Graft vs Host Disease
- Granulomatosis with Polyangiitis
- Hamartoma
- Hamartoma Syndrome, Multiple
- Headache
- Hot Flashes
- Hyperglycemia
- Hypertension
- Hypertension, Pregnancy-Induced
- Idiopathic Pulmonary Fibrosis
- IgA Vasculitis
- Inflammation
- Insulin Resistance
- Lymphangioleiomyomatosis
- Migraine Disorders
- Multiple System Atrophy
- Muscular Diseases
- Neoplasms
- Parkinson Disease
- Personality Disorders
- Polyarteritis Nodosa
- Pulmonary Alveolar Proteinosis
- Pulmonary Fibrosis
- Pure Autonomic Failure
- Purpura
- Sandhoff Disease
- Shock
- Shock, Septic
- Shy-Drager Syndrome
- Sleep Initiation and Maintenance Disorders
- Stroke
- Syndrome
- Systemic Vasculitis
- Tachycardia
- Tay-Sachs Disease
- Vaginitis
- Vasculitis
Recent trials (50)
- NCT07257484CollaboratorPhase 4Jan 5, 2026
- NCT06792500CollaboratorPhase 1/Phase 2Sep 30, 2025
- NCT06822049CollaboratorPhase 2/Phase 3Mar 10, 2025
- NCT06463743CollaboratorPhase 2Jan 31, 2025
- NCT06538285CollaboratorPhase 2Jan 31, 2025
- NCT06736769CollaboratorPhase 2Jan 31, 2025
- NCT06704191CollaboratorPhase 1/Phase 2Dec 6, 2024
- NCT06703216CollaboratorPhase 1/Phase 2Dec 1, 2024
- NCT06668571CollaboratorPhase 2Nov 1, 2024
- NCT06307548CollaboratorPhase 1/Phase 2Jul 30, 2024
- NCT06481150CollaboratorPhase 4Jul 1, 2024
- NCT06274853Lead sponsorPhase 1Jun 15, 2024
- NCT06171724CollaboratorEarly Phase 1Mar 1, 2024
- NCT06175273CollaboratorPhase 2/Phase 3Jan 31, 2024
- NCT06108076CollaboratorEarly Phase 1Nov 30, 2023
Details
- Founded
- Bethesda, MD, US Jan 1, 2011
- Last known activity
- Jan 5, 2026